To analyze the clinical efficacy of recombinant type Ⅲ humanized collagen vaginal agar-agar in the treatment of vaginal dryness. Methods A total of 100 patients with vaginal dryness who were treated in Chengdu Jinjiang Angela Medical Cosmetology Hospital from January to December 2022 were selected as the research objects. They were divided into reference group and analysis group by red and blue envelope method, with 50 patients in each group. The reference group was treated with hyaluronic acid derivative vaginal gel, and the analysis group was treated with recombinant type Ⅲ humanized collagen vaginal agar-agar. The vaginal treatment effect, quality of sexual intercourse, satisfaction and safety were compared between the two groups. Results After intervention, the scores of vaginal elasticity, vaginal wettability and vaginal secretion in the analysis group were higher than those in the reference group (P <0.05). After intervention, the scores of vaginal dryness tingling and sexual intercourse pain in the analysis group were higher than those in the reference group (P <0.05). The total satisfaction of the analysis group was higher than that of the reference group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P >0.05). Conclusion For patients with vaginal dryness, the application of recombinant type Ⅲ humanized collagen vaginal agar-agar can improve the effect of vaginal treatment and improve the quality of sexual intercourse. It has high safety and high patient satisfaction.